FitLife Q4 rev +13% to $15M; FY24 adj EBITDA +39% to $14.1M; Q1 2025 rev seen -4-6%

FITLIFE BRANDS, INC.

Q4 2024 revenue $15.0M (+13% YoY), net income $2.1M ($0.21 diluted EPS), adjusted EBITDA $3.1M (+31%).
FY24 revenue $64.5M (+22%), net income $9.0M (+70%), adj EBITDA $14.1M (+39%); net debt $8.6M (0.6x adj EBITDA).
GNC commercial dispute settled Jan 2025; Legacy FitLife Q4 wholesale down 20% due to order halt, now selling directly to franchisees.
MusclePharm Q4 revenue $2.8M (+14% seq); launched Pro Series at Vitamin Shoppe and new RTD protein; rebranding underway.
Q1 2025 prelim: revenue down 4-6% YoY (MRC seasonality, leap year), adj EBITDA flat; China tariffs may raise COGS, mitigating via raw material stockpiling.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.